CTRI/2019/02/017532尚未招募2 期
To Evaluate the Safety and Efficacy of HODT101510A in Indigestion: Randomized, Open Label, One Arm Clinical Study - QDEE-IND
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Adult male and female subjects aged >=18 years presenting with either one or more of the following indigestion symptoms like Loss of appetite, nausea, bloating, belching, abdominal discomfort, flatulence.
- •Subjects who are willing to withdraw from any other medication taken for indigestion.
- •Subjects willing to sign informed consent and follow the study procedure.
- •Subjects who has not participated in any similar kind of clinical study in the last one month.
排除标准
- •Patients who took any other medications to relieve these symptoms within 2 weeks. Subjects with cardiac, neurological, renal or hepatic dysfunction. A known history or present condition of allergic response to products its components or to any of the ingredients in the test product. Pre-existing systemic disease requiring long-term medications. Pregnant & breast-feeding women.
研究者
相似试验
招募中
2 期
To Evaluate the Efficacy and Safety of thyroid capsule in the Management of Subclinical Hypothyroidism- An Open Label Clinical Studyâ??CTRI/2019/12/022481The Himalaya Drug Company Ltd
尚未招募
2 期
Clinical Study on â??SHL 1055â?? Tablet in Liver Disorder.CTRI/2018/04/013034SAVESTA LIFESCIENCES INC
招募中
不适用
Assessment of the safety and performance of the HARPOON* Beating Heart Mitral Valve Repair System; a multi-center post-market study (The ASCEND Study).NL-OMON50870HARPOON Medical, an indirect wholly-owned subsidiary of Edwards Lifesciences Corporation20
招募中
3 期
Evaluation of the safety and efficacy of the HiFocus V electrode array in adults with severe-to-profound hearing loss through analysis of post-implant benefits of the HarmonyTM HiResolutionTM Bionic Ear cochlear implant systemsevere-to-profound hearing loss10019243deafnessNL-OMON35760Advanced Bionics Corporation15
已完成
3 期
Evaluation of safety and efficacy of Controlled release Hydrochlorothiazide in stage I Essential HypertensioCTRI/2013/07/003793Ipca Laboratories Ltd Mumbai54